title: Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo.
abstract: The safety and efficacy of a new topical antiinfective agent, mupirocin, was compared with that of oral erythromycin ethylsuccinate in the treatment of impetigo in children. Sixty-two children aged 5 months to 13 years with impetigo were assigned to be treated with either mupirocin in three daily applications or erythromycin ethylsuccinate (40 mg/kg of body weight per day divided into four doses) according to a randomized treatment schedule. On the initial visit, exudate or cleansed infected sites or both were cultured and therapy was begun. All patients were treated for 8 days. Patients were seen again on days 4 to 5 of therapy, at the end of therapy, and 7 days after the end of therapy. Sites of infection were comparable between the groups, as were bacteriologic responses. At the first visit, 24 of 30 children in the mupirocin group and 14 of 32 children in the erythromycin group were cured or had at least a 75% reduction in size of the lesions. At the end of the study, all 29 of the children in the mupirocin group who came to follow-up, compared with 27 of 29 in the erythromycin group, were cured. Side effects were few. Five children in the erythromycin group developed mild diarrhea. Thus, mupirocin appears to be safe and effective in treating impetigo in children. Our data show a trend toward more rapid clinical response with mupirocin than with erythromycin.
authors.affiliation: Division of Pediatric Pharmacology and Critical Care, Rainbow Babies and Childrens Hospital, Cleveland, Ohio.
authors.forename: J
authors.initials: J
authors.lastname: Goldfarb
authors.forename: D
authors.initials: D
authors.lastname: Crenshaw
authors.forename: J
authors.initials: J
authors.lastname: O'Horo
authors.forename: E
authors.initials: E
authors.lastname: Lemon
authors.forename: J L
authors.initials: JL
authors.lastname: Blumer
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004917:Erythromycin / Q000009:adverse effects / Q000627:therapeutic use*; D005227:Fatty Acids / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007169:Impetigo / Q000188:drug therapy*; D007223:Infant; D008297:Male; D016712:Mupirocin; D011897:Random Allocation
chemical_list: D000900:Anti-Bacterial Agents; D005227:Fatty Acids; D004917:Erythromycin; D016712:Mupirocin